Change in coreceptor use correlates with disease progression in HIV-1--infected individuals - PubMed (original) (raw)

Change in coreceptor use correlates with disease progression in HIV-1--infected individuals

R I Connor et al. J Exp Med. 1997.

Abstract

Recent studies have identified several coreceptors that are required for fusion and entry of Human Immunodeficiency Virus type 1 (HIV-1) into CD4+ cells. One of these receptors, CCR5, serves as a coreceptor for nonsyncytium inducing (NSI), macrophage-tropic strains of HIV-1, while another, fusin or CXCR-4, functions as a coreceptor for T cell line-adapted, syncytium-inducing (SI) strains. Using sequential primary isolates of HIV-1, we examined whether viruses using these coreceptors emerge in vivo and whether changes in coreceptor use are associated with disease progression. We found that isolates of HIV-1 from early in the course of infection predominantly used CCR5 for infection. However, in patients with disease progression, the virus expanded its coreceptor use to include CCR5, CCR3, CCR2b, and CXCR-4. Use of CXCR-4 as a coreceptor was only seen with primary viruses having an SI phenotype and was restricted by the env gene of the virus. The emergence of variants using this coreceptor was associated with a switch from NSI to SI phenotype, loss of sensitivity to chemokines, and decreasing CD4+ T cell counts. These results suggest that HIV-1 evolves during the course of infection to use an expanded range of coreceptors for infection, and that this adaptation is associated with progression to AIDS.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Inhibition of sequential HIV-1 isolates by β-chemokines. Biologically cloned isolates of HIV-1 were used to infect PHA-activated normal donor PBMCs in the presence of increasing concentrations of RANTES (▪), MIP-1α (•), MIP-1β (▴), or all three combined (♦). HIV-1 p24 antigen was measured in culture supernatants on day 7 after virus inoculation. The percent inhibition was calculated based on control cultures infected without added chemokines.

Figure 2

Figure 2

Coreceptor use by primary HIV-1 env-pseudotyped virions. (A) HOS.CD4 expressing either CCR1, CCR2, CCR3, CCR4, CCR5, or CXCR-4 were infected with HIV-1 virions carrying a luciferase reporter gene and pseudotyped with envelope glycoproteins from either control viruses (HIV-1JRFL, HIV-1HXB2) or from primary virus env clones. Three of the primary env clones came from a patient with rapid disease progression (–, –, 15-1), while the fourth clone was from a patient with long-term asymptomatic infection (DH). Luciferase activity was calculated by subtracting the background measurements made using env(−) virions and HOS.CD4 cells expressing only the retroviral vector, pBABE. (B) Deduced amino acid sequences of the V3 domain of gp120 from cloned primary HIV-1 env genes. Bold type indicates amino acids at positions 11 and 28 which are associated with the SI phenotype of the virus (35, 36).

Figure 2

Figure 2

Coreceptor use by primary HIV-1 env-pseudotyped virions. (A) HOS.CD4 expressing either CCR1, CCR2, CCR3, CCR4, CCR5, or CXCR-4 were infected with HIV-1 virions carrying a luciferase reporter gene and pseudotyped with envelope glycoproteins from either control viruses (HIV-1JRFL, HIV-1HXB2) or from primary virus env clones. Three of the primary env clones came from a patient with rapid disease progression (–, –, 15-1), while the fourth clone was from a patient with long-term asymptomatic infection (DH). Luciferase activity was calculated by subtracting the background measurements made using env(−) virions and HOS.CD4 cells expressing only the retroviral vector, pBABE. (B) Deduced amino acid sequences of the V3 domain of gp120 from cloned primary HIV-1 env genes. Bold type indicates amino acids at positions 11 and 28 which are associated with the SI phenotype of the virus (35, 36).

Similar articles

Cited by

References

    1. Cheng-Mayer C, Seto D, Tateno M, Levy JA. Biologic features of HIV-1 that correlate with virulence in the host. Science (Wash DC) 1988;240:80–82. - PubMed
    1. Connor RI, Ho DD. Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J Virol. 1994;68:4400–4408. - PMC - PubMed
    1. Fenyö E, Morfeldt-Måson L, Chiodi F, Lind B, Von Gegerfelt A, Albert J, Åsjö B. Distinctive replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol. 1988;62:4414–4419. - PMC - PubMed
    1. Schuitemaker H, Koot M, Kootsra NA, Wouter-Dercksen M, de Goede REY, Van Steenwijk RP, Lange JMA, Eeftink-Schattenkerk JKM, Miedema F, Tersmette M. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell tropic virus populations. J Virol. 1992;66:1354–1360. - PMC - PubMed
    1. Connor RI, Mohri H, Cao Y, Ho DD. Increased viral burden and cytopathicity correlate temporally with CD4+T-lymphocyte decline and clinical progression in HIV-1 infected individuals. J Virol. 1993;67:1772–1778. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources